Del Carmen Jeffrey's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 13, 2024
- Accession no.
- 0001161697-24-000341
- Filed
- Aug 13, 2024
- Trade date
- Aug 9, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $664.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Del Carmen JeffreyCIK 0001816477 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −6,058 | $18.44F1 | −$111,709.52 | 12,369 | Direct | |
| Aug 9, 2024 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +30,000 | $2.86 | +$85,800 | 42,369 | Direct | |
| Aug 9, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −30,000 | $18.42F1,F2 | −$552,600 | 12,369 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 804,019 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
Referenced by the price of 2 transactions in Table I.
- F2
Shares were sold in various lots from $18.33 to $18.48 per share. The price listed represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.